The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies.
Ontology highlight
ABSTRACT: The increase in the number of therapeutic alternatives for both newly diagnosed and relapsed/refractory multiple myeloma (RRMM) patients has widened the clinical scenario, leading to a level of complexity that no algorithm has been able to cover up to date. At present, this complexity increases due to the wide variety of clinical situations found in MM patients before they reach the status of relapsed/refractory disease. These different backgrounds may include primary refractoriness, early relapse after completion of first-line therapy with latest-generation agents, or very late relapse after chemotherapy or autologous transplantation. It is also important to bear in mind that many patient profiles are not fully represented in the main randomized clinical trials (RCT), and this further com
SUBMITTER: Hernandez-Rivas JA
PROVIDER: S-EPMC8743063 | biostudies-literature | 2022 Jan
REPOSITORIES: biostudies-literature
ACCESS DATA